DGX logo

Quest Diagnostics Incorporated Stock Price

NYSE:DGX Community·US$21.4b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 32 Fair Values set on narratives written by author

DGX Share Price Performance

US$193.82
24.20 (14.27%)
US$223.25
Fair Value
US$193.82
24.20 (14.27%)
13.2% undervalued intrinsic discount
US$223.25
Fair Value
Price US$193.82
AnalystConsensusTarget US$223.25

DGX Community Narratives

·
Fair Value US$223.25 13.2% undervalued intrinsic discount

DGX: Core Volume Momentum And New Blood Tests Will Drive Share Momentum

0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative

Trending Discussion

Updated Narratives

DGX logo

DGX: Refreshed 2026 Outlook And Margin Assumptions Will Sustain Safe Haven Appeal

Fair Value: US$223.25 13.2% undervalued intrinsic discount
18 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued established dividend payer.

1 Risk
4 Rewards

Quest Diagnostics Incorporated Key Details

US$11.3b

Revenue

US$7.5b

Cost of Revenue

US$3.8b

Gross Profit

US$2.7b

Other Expenses

US$1.0b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
9.21
33.28%
9.04%
73.1%
View Full Analysis

About DGX

Founded
1967
Employees
51500
CEO
James Davis
WebsiteView website
www.questdiagnostics.com

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer’s disease; and women’s health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Recent DGX News & Updates

Narrative Update May 13

DGX: Refreshed 2026 Outlook And Margin Assumptions Will Sustain Safe Haven Appeal

Quest Diagnostics' analyst price target has been revised to $223.25 from $218.19 as analysts factor in recent target increases across the Street and updated assumptions around discount rate, profit margins and future P/E multiples. Analyst Commentary Recent Street research around Quest Diagnostics has centered on refreshed valuation work and price target changes, with several firms adjusting their numbers based on updated assumptions for discount rates, profit margins and future P/E multiples.
Seeking Alpha May 07

Quest Diagnostics: Updating Levels After Q1 Earnings

Summary Quest Diagnostics delivered strong Q1 results with 9.2% revenue growth and 13% EPS growth, driving management to raise 2026 guidance. DGX's growth is fueled by advanced diagnostics, robust consumer and hospital channels, and efficiency gains from AI and automation. Key risks include margin pressure from lower-priced partnership volumes and potential Medicare reimbursement cuts under PAMA. I maintain a 5/5 conviction rating, raising my Buy Threshold to $197 and holding the Sell Target at $227, reflecting confidence in DGX's long-term outlook. Read the full article on Seeking Alpha

Recent updates

No updates